Document is current
Any future updates will be listed below
-
Authors
Marotte, Hubert https://orcid.org/0000-0003-1177-9497
Cantagrel, Alain https://orcid.org/0000-0001-8890-9099
Coury, Fabienne https://orcid.org/0000-0002-9175-8620
Schaeverbeke, Thierry https://orcid.org/0000-0002-6976-643X
Assing, Maryse
Kessouri, Meriem https://orcid.org/0000-0001-9967-3210
Brault, Yves https://orcid.org/0009-0000-2305-5387
Fautrel, Bruno https://orcid.org/0000-0001-8845-4274
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02925338 at ClinicalTrials.govDocuments that mention this clinical trial
Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT)
https://doi.org/10.1007/s12325-025-03304-6
-
Funding
Funding for this research was provided by:
Pfizer
CHU Saint-Étienne
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 1 July 2025
First Online: 28 July 2025
Declarations
:
: Hubert Marotte has received consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Biogen Bristol-Myers Squibb, Celltrion, Eli Lilly, Fresenius Kabi, Galapagos, Janssen, Medac, NORDIC Pharma, Novartis, Pfizer, and UCB. Alain Cantagrel has received consulting fees from Eli Lilly and Janssen and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Medac, Novartis, Pfizer, and UCB. Fabienne Coury has received research grants paid to her institution (Hospices Civils de Lyon, Lyon Recherche Clinique) from Biogen, Chugai, Novartis, and UCB; consulting fees from Amgen, Chugai, Janssen, Eli Lilly, and UCB; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie and Eli Lilly; and support for travel from AbbVie and Eli Lilly. Thierry Schaeverbeke: has received research support from AbbVie, Abivax, Biogen, Eli Lilly, MSD, Novartis, Pfizer, and Sandoz; consulting fees for advisory boards from AbbVie, Bristol-Myers Squibb, Eli Lilly, Novartis, Pfizer, and Sanofi; and payment or honoraria for educational events from AbbVie, Biogen, Bristol-Myers Squibb, Eli Lilly, Galapagos, Janssen, Nordic Pharma, Novartis, Pfizer, and Viatris. Bruno Fautrel has received consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Chugai, Eli Lilly, Fresenius Kabi, Galapagos, Janssen, Medac, MSD, NORDIC Pharma, Novartis, OWKIN, Pfizer, Roche, Sandoz, Sanofi-Genzyme, SOBI, UCB, and Viatris. Maryse Assing, Yves Brault, and Meriem Kessouri are employees of and hold stock or stock options in Pfizer.
: Patients (or their legal representatives) completed a written informed consent form and authorized access to their clinical data and medical records before enrollment. This observational study was registered with the National Commission on Data Processing and Freedoms. This study was conducted in accordance with the Declaration of Helsinki and was approved by the French Advisory Committee on the Treatment of Information in Health Research (CCTIR number 16-207; 23/03/2016) and by the French Data Protection Authority (CNIL) (approval ref: MMS/VCS/ARS169124/request number: 916228; 30/09/2016)), which were the requirements at the time this study was conducted.
